Cytokine Storms in Cancer and COVID-19.


Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
09 11 2020
Historique:
pubmed: 12 10 2020
medline: 1 12 2020
entrez: 11 10 2020
Statut: ppublish

Résumé

During the COVID-19 pandemic, research on "cytokine storms" has been reinvigorated in the field of infectious disease, but it also has particular relevance to cancer research. Interleukin-6 (IL-6) has emerged as a key component of the immune response to SARS-CoV-2, such that the repurposing of anti-IL-6 therapeutics for COVID-19 is now a major line of investigation, with several ongoing clinical trials. We lay a framework for understanding the role of IL-6 in the context of cancer research and COVID-19 and suggest how lessons learned from cancer research may impact SARS-CoV-2 research and vice versa.

Identifiants

pubmed: 33038939
pii: S1535-6108(20)30493-1
doi: 10.1016/j.ccell.2020.09.019
pmc: PMC7531591
pii:
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

598-601

Informations de copyright

Published by Elsevier Inc.

Références

N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Nat Rev Cancer. 2016 Aug;16(8):525-37
pubmed: 27388699
Lancet Oncol. 2002 Aug;3(8):461-9
pubmed: 12147432
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Cell. 2020 Jun 25;181(7):1475-1488.e12
pubmed: 32479746
J Clin Invest. 2013 Dec;123(12):5247-57
pubmed: 24231352
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503877
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Cell Stem Cell. 2020 Dec 3;27(6):962-973.e7
pubmed: 32979316
Lancet Rheumatol. 2020 Oct;2(10):e603-e612
pubmed: 32838323
Oncogene. 2006 Jul 20;25(31):4300-9
pubmed: 16518408
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Nat Rev Rheumatol. 2020 Jun;16(6):335-345
pubmed: 32327746
Cancer Cell. 2005 Mar;7(3):211-7
pubmed: 15766659

Auteurs

Casmir Turnquist (C)

University of Oxford Medical School, John Radcliffe Hospital, Oxford, UK; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Bríd M Ryan (BM)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Izumi Horikawa (I)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Brent T Harris (BT)

Departments of Neurology and Pathology, Georgetown University Medical Center, Washington, DC 20007, USA.

Curtis C Harris (CC)

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: curtis_harris@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH